Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:23:20 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:HCM from 2023-05-04 to 2024-05-03 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 08:30U:HCMNews ReleaseHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
2024-04-05 04:30U:HCMNews ReleaseHUTCHMED Highlights Data to be Presented at AACR Congress 2024
2024-04-02 00:30U:HCMNews ReleaseHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2024-03-27 20:00U:HCMNews ReleaseHUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
2024-03-21 20:00U:HCMNews ReleaseHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
2024-02-28 06:30U:HCMNews ReleaseHUTCHMED Reports 2023 Full Year Results and Provides Business Updates
2024-02-06 19:00U:HCMNews ReleaseHUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
2024-02-02 03:30U:HCMNews ReleaseHUTCHMED Announces that Inmagene Exercises Option to License Two ‚  Drug ‚  Candidates as Part of Strategic Partnership
2024-02-01 03:30U:HCMNews ReleaseHUTCHMED to Announce 2023 Final Results
2024-01-29 23:54U:HCMNews ReleaseHUTCHMED Receives ELUNATE ‚ ® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
2024-01-10 19:00U:HCMNews ReleaseHUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
2023-12-12 23:30U:HCMNews ReleaseHUTCHMED Announces Continued Inclusion of ELUNATE ‚ ® (fruquintinib) and SULANDA ‚ ® (surufatinib) in the National Reimbursement Drug List in China at Current ‚  Terms
2023-12-12 19:00U:HCMNews ReleaseHUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
2023-11-30 19:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO ‚  Asia and ESMO Immuno-Oncology Congresses
2023-11-08 19:11U:HCMNews ReleaseHUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA ¢ „ ¢ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
2023-10-16 04:30U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at ESMO ‚  Congress ‚  2023
2023-09-29 04:30U:HCMNews ReleaseHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic ‚  Colorectal ‚  Cancer in Japan
2023-09-12 04:30U:HCMNews ReleaseHUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
2023-09-11 20:00U:HCMNews ReleaseHUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ‚  China
2023-08-28 20:00U:HCMNews ReleaseHUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
2023-08-20 20:00U:HCMNews ReleaseHUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
2023-07-31 07:42U:HCMNews ReleaseHUTCHMED Reports 2023 Interim Results and Provides Business ‚  Updates
2023-07-19 20:00U:HCMNews ReleaseHUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
2023-07-13 04:30U:HCMNews ReleaseHUTCHMED Announces Changes to Board of Directors and Technical ‚  Committee ‚  
2023-07-09 20:00U:HCMNews ReleaseHUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
2023-06-26 04:30U:HCMNews ReleaseHUTCHMED to Announce 2023 Half-Year Financial Results
2023-06-15 20:30U:HCMNews ReleaseHUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The ‚  Lancet
2023-06-15 10:30U:HCMNews ReleaseTakeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
2023-06-09 05:30U:HCMNews ReleaseHUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
2023-05-25 19:01U:HCMNews ReleaseTakeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer ‚  Granted Priority Review
2023-05-25 18:00U:HCMNews ReleaseHUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
2023-05-12 04:30U:HCMNews ReleaseHUTCHMED Announces Board of Directors and Board ‚  Committee Membership
2023-05-10 04:30U:HCMNews ReleaseHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board ‚  Committees ‚